Research into developing new antimicrobial resistance treatment in Nigeria and other low/middle-income countries has fuelled a ...

The Bill & Melinda Gates Foundation, Novo Nordisk Foundation, and Wellcome are collaborating on a $50 million effort to boost ...

A Cornell University-led collaboration has uncovered the equipment that enables bacteria to survive exposure to antibiotics: ...

Research into developing new antimicrobial resistance treatments in Nigeria and other low/middle-income countries has secured ...

Emblaveo marks the first and only fixed-dose intravenous monobactam/β-lactamase inhibitor combination antibiotic to be ...

Salmonella 'can cause serious and sometimes fatal infections in young children, frail or elderly people, and others with weakened immune systems.' ...

Emblaveo is a fixed-dose IV treatment that combines aztreonam, a monobactam antibiotic, and avibactam, a β-lactamase inhibitor.

AbbVie has announced that the US Food and Drug Administration (FDA) has approved its Pfizer-partnered Emblaveo ...

Glox Therapeutics, a company pioneering the development of precision antibiotic therapies based on naturally occurring bacteriocins, today announced the appointment of Dr Michael Murray as Chair of ...

Emblaveo (aztreonam-avibactam) was approved for treating complicated intra-abdominal infections with limited or no treatment ...

Emblaveo will be available in the third quarter of 2025 to treat patients with intra-abdominal infections, a common cause of sepsis in the intensive care unit.

CAMBRIDGE, MA AND PITTSBURGH, PA / ACCESSWIRE / 10, 2025 / Next Gen Diagnostics (NGD), a pioneer in the development of machine learning models for whol ...